San Diego stem cell treatment company Fate Therapeutics Inc. announced the terms for its approximately $60 million initial public offering. The company will offer 4 million shares priced at $14 to $16 apiece.
At the $15 price, Fate would then command a market value of $219 million, according to investment banking firm Renaissance Capital.
The company plans to list on the Nasdaq under ticker symbol FATE.
Fate Therapeutics, founded in 2007, is comprised of a stem cell team with researchers from Harvard University, Stanford University, the University of Washington, and The Scripps Research Institute.
— Meghana Keshavan